Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Perrigo closes Qualis deal

This article was originally published in The Tan Sheet

Executive Summary

Perrigo completes its acquisition of Des Moines, Iowa-based store-brand pediculicide manufacturer Qualis for $12 mil. cash, the firm announces July 11. The deal, initially announced in March, gives the private labeler five OTC products equivalent to Bayer's Rid and Insight Pharmaceuticals' Nix lice products, which are expected to add more than $10 mil. to annual sales, the Allegan, Mich.-based firm says (1"The Tan Sheet" March 12, 2007, In Brief)...

You may also be interested in...

Perrigo enters lice market

The Allegan, Mich.-based private labeler enters an agreement March 7 to expand its offerings into a new category by paying $12 mil. in cash for Qualis's store-brand pediculicide products in a transaction the firms expect to close around June 30. In a release, Perrigo President and CEO Joe Papa says the acquisition will bring "a range of products that fits nicely within our Consumer Healthcare business portfolio." The firm says adding Des Moines, Iowa-based Qualis's OTC product formulations similar to the Rid and Nix brands should increase its sales by $10 mil. annually...

Keeping Track: US FDA Clears Esperion’s Nexletol, Baudax’ Anjeso, Agile’s Twirla

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.

Esperion’s Nexletol Reaches The Cholesterol Market Priced To Sell

Esperion obtained an on-time approval of Nexletol (bempedoic acid) for a pair of LDL cholesterol-lowering indications on 21 February. 





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts